Overview

Open-Label Pilot Study of Lisdexamfetamine for Cocaine Dependence

Status:
Completed
Trial end date:
2013-12-01
Target enrollment:
Participant gender:
Summary
The proposed protocol is an open-label pilot study of the treatment of cocaine dependence using lisdexamfetamine (LDX), a prodrug of d-amphetamine. The investigators plan to enroll 12 patients in an eight-week open-label trial to obtain preliminary data regarding the safety, tolerability, and potential utility of lisdexamfetamine for treatment of cocaine dependence and to determine an effective dosage range.
Phase:
Phase 1/Phase 2
Details
Lead Sponsor:
New York State Psychiatric Institute
Collaborator:
National Institute on Drug Abuse (NIDA)
Treatments:
Cocaine
Lisdexamfetamine Dimesylate